A decade ago, GLP-1 receptor agonists were a modest addition to the type 2 diabetes toolkit — useful for glucose control, notable for weight loss as a side benefit. Today, they are arguably the most consequential drug class in modern medicine. The evidence has moved so fast that cardiologists, nephrologists, hepatologists, and even addiction specialists are now prescribing them. If you haven’t revisited this class recently, you’re already behind.

The landmark trials of 2023 to 2025 didn’t just expand the indications — they fundamentally changed how we think about obesity, cardiovascular risk, and organ protection. Semaglutide alone has now shown benefit in heart failure with preserved ejection fraction, chronic kidney disease, metabolic liver disease, and major cardiovascular events in people without diabetes. That’s not a lifestyle drug. That’s a disease-modifying agent.

This guide cuts through the noise and gives you what you actually need at the bedside: the mechanism, the key trial data, the expanding indications, practical prescribing guidance, and the safety signals you cannot afford to miss.

What Are GLP-1 Receptor Agonists?

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the small intestine in response to food. It works through a specific receptor — the GLP-1 receptor — found not just in the pancreas, but also in the heart, kidneys, brain, liver, and gut. This widespread receptor distribution is precisely why this drug class has such broad systemic effects.

GLP-1 receptor agonists (GLP-1 RAs) are synthetic molecules that mimic or amplify native GLP-1 activity, with a much longer half-life than the endogenous hormone (which is degraded within minutes by DPP-4 enzymes).

The Evidence in 2026 — Key Trial Data That Changed Practice

The evidence base for GLP-1 RAs has exploded since 2021. These are the trials every clinician should know. The numbers speak for themselves.

The SELECT trial deserves particular attention. It enrolled over 17,600 people with established cardiovascular disease and obesity — but no diabetes. Semaglutide cut the risk of heart attack, stroke, and cardiovascular death by 20% over roughly three years. This single trial permanently changed the conversation: GLP-1 RAs are no longer just diabetes drugs.

Expanding Indications: Where GLP-1 RAs Are Heading in 2026

The licensed indications are already broad, but the pipeline is even broader. Here’s where the evidence currently sits across specialties.

1. Cardiovascular Protection (Beyond Diabetes)

Following SELECT, the FDA approved semaglutide 2.4mg (Wegovy) specifically for reduction of cardiovascular events in adults with obesity or overweight and established cardiovascular disease — regardless of diabetes status. This is a paradigm shift. Cardiologists now need to be comfortable initiating GLP-1 RAs, not just endocrinologists.

2. Chronic Kidney Disease

The FLOW trial established semaglutide as the first GLP-1 RA with proven kidney-protective outcomes in CKD. The benefit was seen on top of SGLT2 inhibitors and renin-angiotensin system blockers, suggesting additive protection. Current thinking favours a “triple therapy” approach in high-risk CKD: RAS blockade + SGLT2 inhibitor + GLP-1 RA.

3. Metabolic Dysfunction-Associated Steatohepatitis (MASH)

MASH — previously called NASH — affects an estimated 3–5% of the global population and has no approved treatment until recently. The ESSENCE trial showed that semaglutide achieved MASH resolution (without worsening fibrosis) in nearly 63% of patients compared to 34% on placebo. The FDA approved semaglutide for MASH in early 2025 — the first drug to achieve this milestone.

4. Heart Failure with Preserved Ejection Fraction (HFpEF)

HFpEF in obese patients is a notoriously difficult condition to treat. The STEP-HFpEF trial showed that semaglutide improved quality of life scores (KCCQ), reduced systemic inflammation (CRP), and produced meaningful weight loss — all without worsening cardiac function. Current guidance now supports GLP-1 RA use in obese HFpEF patients.

5. Addiction and Compulsive Behaviours (Emerging Evidence)

Perhaps the most surprising frontier: observational data and early trials suggest GLP-1 RAs reduce alcohol consumption, smoking behaviour, and compulsive eating independently of weight loss — likely via central GLP-1 receptor activity in dopaminergic reward pathways. Clinical trials in alcohol use disorder are underway. Watch this space.

Available Agents in 2026: A Practical Comparison

Not all GLP-1 RAs are the same. The choice of agent depends on indication, route, frequency, patient preference, and access. Tirzepatide (a dual GIP/GLP-1 agonist) has now overtaken semaglutide in weight loss efficacy — though both remain excellent options.

Who Should NOT Be on a GLP-1 RA

Practical Prescribing: Getting the Start-Up Right

The most common reason GLP-1 RAs are stopped is gastrointestinal intolerance — nausea, vomiting, and diarrhoea. This is almost always a dose-escalation problem, not a drug problem. A slow, structured titration is the difference between a patient who tolerates it well and one who stops after two weeks.

Common Mistakes Clinicians Make with GLP-1 RAs

As prescribing has widened beyond endocrinology, certain consistent errors have emerged. Recognising them will protect your patients — and your clinical practice.

A Note for Patients

You may have heard about Ozempic or Wegovy — perhaps from the news, a friend, or social media. These medications are real, effective, and backed by strong scientific evidence. But they are not miracle drugs, and they are not suitable for everyone.

If your doctor has suggested a GLP-1 medication, it is because your weight, diabetes, heart disease, or kidney health means the benefits significantly outweigh the risks for you specifically. These injections work by helping your body feel fuller sooner, lowering your blood sugar more gently, and protecting your heart and kidneys in ways that go beyond the number on the scale.

Side effects — particularly nausea — are common at the start but usually improve within a few weeks. The most important thing you can do is follow your doctor’s titration schedule and not rush to higher doses. Slow and steady gives your body time to adjust, and the results are worth it. Never stop taking this medication without speaking to your doctor first.

Summary

• GLP-1 receptor agonists work via widespread GLP-1 receptors in the pancreas, brain, heart, kidneys, and liver — explaining their broad systemic effects.
• The SELECT trial proved semaglutide reduces major cardiovascular events by 20% in obese patients without diabetes — a landmark shift in prescribing.
• The FLOW trial established GLP-1 RAs as kidney-protective agents; ESSENCE confirmed benefit in MASH.
• Tirzepatide (dual GIP/GLP-1) achieves up to 22.5% weight loss — the highest seen with any approved medical treatment for obesity.
• Absolute contraindications include personal/family history of MTC and MEN 2.
• Slow dose titration is essential — most GI intolerance is avoidable with proper escalation.
• Stop weekly agents 1 week before elective procedures requiring general anaesthesia.
• These are chronic disease medications — weight and metabolic benefit returns when stopped.
• In high-risk CKD, consider combining RAS blockade + SGLT2 inhibitor + GLP-1 RA for maximum organ protection.

References

1. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311–322.
2. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844.
3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
5. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
6. Perkovic V, et al. Semaglutide and Kidney Outcomes in T2DM and CKD (FLOW). N Engl J Med. 2024;391(12):1113–1124.
7. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure and Preserved Ejection Fraction (STEP-HFpEF). N Engl J Med. 2023;389(12):1069–1084.
8. Sanyal AJ, et al. Semaglutide in MASH with Liver Fibrosis (ESSENCE). N Engl J Med. 2024;391(26):2526–2540.
9. American Diabetes Association. Standards of Care in Diabetes — 2026. Diabetes Care. 2026;49(Suppl 1).
10. NICE. Semaglutide for managing overweight and obesity (TA875). National Institute for Health and Care Excellence. 2023.